RMI Partners

RMI Patners - a pharmaceutical project management company with a focus on investments to out of the box developments in medical, pharmaceutical and biotechnology sectors worldwide.

The company’s key mission – to develop and introduce innovative drugs and medical equipment into the market and to create world-class Russian domiciled expertise in Life Sciences venture financing.

Leonid Melamed"It is strategically important that Russian developers of innovative pharmaceuticals appear large in number. Three or thirty companies of this kind in place will not resolve the problem. In the Silicon valley - there are tens of thousands of them, therefore the probability of success is rather high. Drug development industry is alive only if millions of people are dealing with it consolidated in tens of thousands of companies. To make this happen at our place, people with good ideas should be aware of how to become an accurate applicant, and also there must be institutions willing to invest and perform a function of business angels".

Media Center

  • 22 March 2018

    GMP Inspection practice: a case for global benchmarking, convergence and mutual reliance/recognition

    In 1969 the global agreement on the Certification Scheme on the Quality of Pharmaceutical Products Moving in International Commerce was proposed by WHO. The aim was to facilitate international trade in pharmaceuticals through mutual recognition of GMP inspection results. Today, almost 50 years later, up to one hundred countries conduct foreign inspections. As a result a manufacturing site well established, might be inspected  many times in one year by local and different foreign authorities. This leads to duplication of work and waste of recourses both by regulators and industry.

  • 22 March 2018

    Kaluga is expected to complete its program for radiopharmaceuticals in two years

    Kaluga pharmaceutical cluster recently increased the number of locally manufactured drugs from 65 to 154. The Governor Anatoly Artamonov expects that the region needs 2 more years to complete its import substitution program for radiopharmaceuticals, reported Kaluzhskaya Nedelya, a local newspaper.

  • 21 March 2018

    Blockchain technology has a special potential to confront counterfeit drugs

    DHL has released a trend report in cooperation with Accenture, a leading global technology consultant, on blockchain technology’s potential to transform the logistics industry. The report includes initial findings on a working prototype developed by DHL and Accenture, which tracks pharmaceuticals from the point of origin to the consumer, preventing tampering and errors.

  • 20 March 2018

    Russia establishes its National Quality Infrastructure Council

    On March 14, Denis Manturov, the Russian Minister of Industry and Trade, chaired a meeting of the State Commission on Counteraction to Illegal Circulation of Industrial Products. The Minister said that, ensuring the “market purity” would require, in addition to providing more preferences for entrepreneurs operating strictly within the legal field, to guarantee to potential consumers that they purchase genuine rather than counterfeit and falsified products.

Read more